Fig. 5

(A, B) AUC curves for the risk assessment model constructed using key prognostic genes. (C) Survival analyses for high and low Riskscore groups in the GEO-meta cohort. (D) Validation of survival analyses for the risk assessment model in the TCGA-PDAC cohort. (E) Validation of survival analyses for the risk assessment model in the GSE85916 cohort. (F) Boxplot of differential expression of immune checkpoint genes between high and low Riskscore groups. (G) Boxplot of drug sensitivity between high-risk and low-risk groups. (* p < 0.05; ** p < 0.01; *** p < 0.001)